Quoin Pharmaceuticals Ltd. has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for their lead product, QRX003, for the treatment of Netherton Syndrome. This designation provides Quoin Pharmaceuticals with incentive benefits such as scientific advice on study protocols, fee reductions, and access to EU grants. If approved, QRX003 will receive 10 years of market exclusivity in Europe. QRX003 is currently undergoing multiple late-stage clinical trials as a topical, non-systemic treatment for Netherton Syndrome, a condition for which no approved therapies currently exist.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.